News sentiment analysis powered by sentiment-insight.com
Alcon slightly misses Q3 net sales, narrows full-year...
Swiss eye-care company Alcon reported third-quarter sales that were slightly below expectations, dragged by inflation and negative currency effects. The company, which was spun off from Novartis in 2019, reported a net profit of $327 million. Alcon narrowed its full-year outlook.
Here’s Why Fiserv (FI) Declined in Q3 Madison Investments, an investment advisor, released its “Madison Investors Fund’ third quarter 2023 investor letter. Fiserv, Inc. (NYSE:FI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. The bottom five individual contributors of the fund were Dollar Tree,. Analog Devices, Lowe’s Companies, and Alcon.
Save on Bestselling Contact Lenses With This Fall Sale With code HAPPYFALL, get 15% off all orders and free shipping for a limited time. Acuvue Oasys 1-Day contact lenses feature a tear-infused design for extra lubrication. Alcon Precision Contact Lenses contain a micro-thin layer of moisture around each lens.
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? Alcon (VTX:ALC) has had a rough week with its share price down 3.3%. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term. Particularly, we will be paying attention to Alcon's ROE today. ROE measures how effectively a company can generate returns on the investment it received from its shareholders.
Alcon raises full-year outlook, reports 9% Q2 net sales... Alcon sees net sales growth in constant currency in the range of 9% to 11% in 2023. Alcon reported a 9% rise in net sales in three months ended June 30. quarterly net sales were at $2.4 billion.
Alcon (VTX:ALC) Shareholders Will Want The ROCE Trajectory To Continue Alcon's (VTX:ALC) return on capital employed (ROCE) is 3.1%. That's a low return, and it under-performs the Medical Equipment industry average of 14%. The company has increased its ROCE by 516% in the last five years. It's worth investigating what the management team has planned for long term growth.
Alcon reports 7% Q1 sales rise, notches up 2023 sales outlook Alcon said group revenue rose by 7% in the first quarter. Swiss-American eye care group reported first-quarter net sales of $2.33 billion. It slightly raised its full-year outlook for net sales.
Allergic Rhinitis Drugs Market to hit USD 16 billion by 2032, says GMI Rise in air pollution levels results in high allergenic pollen and contributes to a high number of patients suffering from allergic Rhinitis. Around 70% of American households own a pet, inviting allergic diseases. Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Stallergenes Greer, Sanofi S.A., Boehringer Ingelheim, Unichem Laboratories, and others.
Allergic Rhinitis Drugs Market to hit USD 16 billion by 2032, says GMI Rise in air pollution levels results in high allergenic pollen and contributes to a high number of patients suffering from allergic rhiniti. Around 70% of American households own a pet, inviting allergic diseases which is likely to fuel product demand. Teva Pharmaceutical Industries Ltd., Alcon (Novartis AG), Stallergenes Greer, Sanofi S.A., Boehringer Ingelheim, Unichem Laboratories, and others.
ALC vs. ISRG: Which Stock Should Value Investors Buy Now? Investors interested in Medical - Instruments stocks are likely familiar with Alcon (ALC) and Intuitive Surgical, Inc. (ISRG) But which of these two stocks presents...
Ophthalmic Device Global Market Report 2023: Launch of New Biocompatible Materials Bolsters Growth The global ophthalmology device market is being driven by patient demographics such as the rising incidence of diabetes and obesity. The market is dominated by a few players: EssilorLuxottica, Alcon, Bausch & Lomb, Carl Zeiss Meditec, CooperVision, Johnson & Johnson.
We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC) Alcon's (VTX:ALC) return on capital employed (ROCE) is 3.8%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 8.7%. The company is doing well in that sense, and it's worth investigating what the management team has planned for long term growth prospects. If you'd like, you can check out the forecasts from the analysts covering Alcon for free.
Sign Up
